To Evaluate Effectiveness and Safety of Containing Raltegravir in Naive HIV NON B or B Infected Patients

Inclusion Criteria: * In order to be eligible to take part in this study, patients should meet all of the following criteria: Patient aged at least 18 years; Treatment naive patient infected with HIV-1; Patients indicated for treatment containing raltegravir Patient has at least 2 activates molecules in combination therapy according genotype realized in the visit of selection. Patient has not a history or current evidence of opportunist infection within the 4 weeks before the selection Patient who has received oral and written (information sheet) information about the study and who has agreed for the computer processing of his/her personal data. Patients with chronic hepatitis, including chronic hepatitis B and/or C may enter the study as. Exclusion Criteria: * Patients meeting one or both of the following criteria may not take part in the study * Patient is reproductive potential without requiring the use of contraception * Patient is pregnant or breast-feeding * Patient using alcohol and\\or drug and\\or the other substance that might interfere with the patient participation * Patient infected by HIV2 * Patient has severe hepatic insufficiency. (liver enzymes \> 5N) * Patient has the following laboratory values during selection * Platelets \< 40.000 cell / mm3 * Haemoglobin \< 8 g / dl during the selection * Neutrophils \< 500 / mm3 * Patient has associated treatments which can have interactions with Raltegravir (Cf RCP Isentress ®) * Patient should be considered by the investigator able to conform to the imperatives of the study procedures